25th May 2016 07:01
LONDON (Alliance News) - Circassia Pharmaceuticals PLC Wednesday said it has begun a registration field study for its grass allergy immunotherapy, to be conducted in over 100 centres in the US, Canada and Europe.
The study will enrol around 1,500 subjects and marks the final phase of clinical testing.
Circassia said that, in previous trials, its grass allergy product candidate achieved "encouraging results". Results from this study are expected in the second half of 2018.
"The start of this registration study represents an important milestone for Circassia as we progress our second novel allergy treatment into the final phase of clinical testing," said Chief Executive Steve Harris in a statement.
"Grass allergy is extremely common, affecting millions of people around the world. However, there is currently no short, simple, long-lasting treatment approved, and we believe our next generation immunotherapy has the potential to address this significant unmet need. We also believe our technology has the potential to revolutionise allergy treatment more broadly, and we are looking forward to receiving the results from our cat allergy pivotal phase III study in the coming weeks," Harris added.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
CIR.L